BioCryst announces publication of data from OLE of APeX-2 trial of ORLADEYO

BioCryst Pharmaceuticals announced that data from the open-label extension, OLE, of the APeX-2 trial of oral, once-daily ORLADEYO for the prophylactic treatment of hereditary angioedema, HAE, in patients 12 years and older have been published online by the Journal of Allergy and Clinical Immunology: In Practice. “We are pleased to share long-term efficacy and safety data from APeX-2 as published in JACI: In Practice. These data further illustrate the potential lasting outcomes that can be appreciated by patients who are treated with oral, once-daily ORLADEYO. We continue to see long-term safety and effectiveness data that reinforce ORLADEYO as an important treatment option for patients with HAE, and we look forward to sharing additional real-world evidence at upcoming medical congresses,” said Dr. Ryan Arnold, chief medical officer of BioCryst. The authors concluded that ORLADEYO was generally well tolerated, provided rapid and sustained reductions in HAE attacks and improved QoL over the study duration of 96 weeks. The results from part 3 of APeX-2 were first presented at the European Academy of Allergy and Clinical Immunology Congress in July 2021.